Sacituzumab govitecan (Synonyms: IMMU-132)

Name: Sacituzumab govitecan
Brand: MedChemExpress
SKU: HY-132254
Rating: 5.0 (10 reviews)

Cat. No.: HY-132254 Purity: 98.02%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity.

For research use only. We do not sell to patients.

CAS No. : 1491917-83-9

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Sacituzumab govitecan:

Sacituzumab govitecan (solution) In-stock

10 Publications Citing Use of MCE Sacituzumab govitecan

Cell Imaging/Staining

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

Bio/Physico-chemical Assay

In Vivo Imaging

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]; Cell morphology was observed under a microscope (SG, 10 nM, 24 h) (Scale bar: 100 µm).

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]; Cell viability was assessed after 24 h of treatment with 10 nM SG at various concentrations using the CCK-8 assay.

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]; Representative fluorescence images and quantification of tail moment in parental and resistant cells (SG, 10 nM, 24 h).

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]; The heatmap displays gene expression in the resistant group compared to the parental group in MCF-7 cells (SG, 10 nM, 24 h). The colors of the heatmap reflect log2 expression levels of genes.

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]; After knockdown of BCL2A1, WFDC3, PI3, CLDN5, and MMP1 separately, the viability of MCF-7-Pa and T47D-Pa was tested at different concentrations of SG (0-200 nM) using CCK-8 assays.

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Anal Chem. 2025 Oct 28;97(42):23598-23608. [Abstract]; Time course of tumor volume of MDA-MB-468 tumor-bearing mice treated with PBS, SG (10 mg/kg, tail vein injection), and Dato-DXd (10 mg/kg, tail vein injection).

: Sacituzumab govitecan purchased from MedChemExpress. Usage Cited in: Anal Chem. 2025 Oct 28;97(42):23598-23608. [Abstract]; MicroPET imaging of MDA-MB-468 tumor-bearing mice at different time postinjection of [⁶⁸Ga]Ga-NOTA-PEG₂-WP8 during PBS, SG (10 mg/kg, tail vein injection) and Dato-DXd (10 mg/kg, tail vein injection) treatment for 0, 9, and 18 days, respectively. White dotted line circles indicate the tumor locations.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Sacituzumab govitecan (10 µM; 48 h) upregulates the early pro-apoptotic signaling markers (cleaved caspase3/7, cleaved PARP, p53 and p21), causes PARP cleavage and apoptosis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	NCI-N87, BxPC-3
Concentration:	10 µM
Incubation Time:	48 h
Result:	Increased cleaved caspase 3/7 and cleaved PARP.

In Vivo

Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) produces significant antitumor effects in mice bearing human gastric cancer xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

157364 (average)

CAS No.

1491917-83-9

Appearance

Solid

Color

White to off-white

SMILES

[Sacituzumab govitecan]

Shipping

Shipping with dry ice.

Storage

-80°C, protect from light

Solvent & Solubility

In Vitro:

H₂O : 25 mg/mL (Need ultrasonic)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.13%

Select Batch:

Data Sheet (270 KB) SDS (418 KB)

COA (232 KB) Others (166 KB) SEC-HPLC (97 KB)

Handling Instructions (2659 KB)

References

[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [Content Brief]

[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512. [Content Brief]

[3]. Cardillo TM, et al., Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [Content Brief]

Sacituzumab govitecan Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sacituzumab govitecan1491917-83-9IMMU-132IMMU132IMMU 132Antibody-Drug Conjugates (ADCs)TROP2Antibody-Drug ConjugatesEGP-1M1S1GA733-1antibody-drug conjugateSN-38pancreatic cancergastric cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Sacituzumab govitecan (Synonyms: IMMU-132)

Customer Review

Other Forms of Sacituzumab govitecan:

Sacituzumab govitecan Related Antibodies

10 Publications Citing Use of MCE Sacituzumab govitecan

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Sacituzumab govitecan Related Antibodies

Molarity Calculator

Dilution Calculator

Sacituzumab govitecan Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report